The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
The U.S. Meals and Drug Administration (FDA) granted orphan drug designation to LP-284, an investigational remedy developed by Lantern Pharma, for sufferers...
For Richard “Rocky” Kimball, a longtime outside fanatic and endurance athlete in Colorado, a prognosis of the uncommon blood most cancers myelodysplastic...
